top of page
Comprehensive Digestive Stool Analysis 2.0™ (CDSA 2.0)

Comprehensive Digestive Stool Analysis 2.0™ (CDSA 2.0)

The Comprehensive Digestive Stool Analysis 2.0™ (CDSA 2.0) is an advanced stool test that provides immediate, actionable clinical information for the management of gastrointestinal health. Utilizing cutting-edge technologies and biomarkers, this test offers valuable insight into digestive function, intestinal inflammation, and the intestinal microbiome.


Sample report


The biomarkers from the CDSA 2.0 Profile are reported using the DIG framework, providing key clinical information for three main gastrointestinal functional areas:

  • Digestion/Absorption:
    • Pancreatic Elastase-1 is a marker of exocrine pancreatic function.
    • Putrefactive Short–Chain Fatty Acids (SCFAs) are markers of undigested protein reaching the colon.
  • Inflammation/Immunology:
    • Calprotectin is a marker of neutrophil-driven inflammation. Produced in abundance at sites of inflammation, this biomarker has been proven clinically useful in differentiating between Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).1,2
    • Eosinophil Protein X is a marker of eosinophil-driven inflammation and allergic response.
  • Gut Microbiome:
    • Metabolic indicators demonstrate specific and vital metabolic functions performed by the microbiota. These include:
      • Beneficial Short–Chain Fatty Acids (SCFA), including n–Butyrate, are fermentation products produced by bacterial action on fiber and resistant starch. N-butyrate is the primary fuel source for colonocytes.
      • pH is influenced by macronutrient composition, bacterial populations, and transit time.
      • Beta-glucuronidase is an enzyme produced by bacteria that relates to the metabolism and detoxification of certain substances.
      • Secondary Bile Acids, including Lithocholic Acid (LCA) and Deoxycholic Acid (DCA), and the LCA/DCA ratio, assess the bacterial conversion of primary bile acids into secondary bile acids.
    • Bacteria and mycology cultures demonstrate the presence of specific beneficial and pathogenic organisms.
    • Bacteria and mycology sensitivities are provided for pathogenic or potentially pathogenic organisms that have been cultured. The report includes effective prescriptive and natural agents.
    • Parasitology
      • CDSA 2.0 provides microscopic fecal specimen examination for ova and parasites (O&P), the gold standard of diagnosis for many parasites.
      • Enzyme immunoassay (EIA), widely recognized for its diagnostic utility in the detection of pathogenic antigens, is used for the identification of CryptosporidiumEntamoeba histolytica, and Giardia lamblia.
      • CDSA 2.0 is also available without parasitology.
  • Additional Biomarkers Available:
    • Campylobacter
    • Clostridium difficile
    • Escherichia coli
    • Helicobacter pylori
    • Macroscopic Exam for Worms
    • KOH Preparation for Yeast
    • Occult blood
    • Fecal Fat
    • Chymotrypsin
    • Zonulin Family Peptide
    • SCFA distribution
    bottom of page